Literature DB >> 19266164

Chronic inflammatory demyelinating polyneuropathy associated with metastatic malignant melanoma of unknown primary origin.

José-Alberto Palma1, Salvador Martín-Algarra.   

Abstract

Paraneoplastic neurological syndromes (PNS) are rare manifestations of malignant disease. It is currently believed that most, if not all, PNS are autoimmune in nature. Proteins expressed on the surface of tumor cells trigger an immune response that cross-reacts with similar proteins in the nervous system, resulting in damage. Moreover, recent studies propose that the appearance of autoimmune phenomena in patients with malignant melanoma implies a strong antitumoral activity and constitutes a marker of improvement in overall survival. We describe a most unusual case of chronic inflammatory demyelinating polyneuropathy (CIDP) occurring in a patient with metastatic malignant melanoma of unknown primary origin who received treatment with interferon alpha-2b. We also review the relevant literature about this infrequent association, discuss on its pathogenesis and underline its importance as surrogate marker, useful to verify the antineoplastic treatment efficacy.

Entities:  

Mesh:

Year:  2009        PMID: 19266164     DOI: 10.1007/s11060-009-9848-x

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  11 in total

1.  Chronic inflammatory polyneuropathy revealing malignant melanoma.

Authors:  A Rousseau; F Salachas; M Baccard; J Y Delattre; M Sanson
Journal:  J Neurooncol       Date:  2005-02       Impact factor: 4.130

2.  Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma.

Authors:  M N Saleh; M B Khazaeli; R H Wheeler; E Dropcho; T Liu; M Urist; D M Miller; S Lawson; P Dixon; C H Russell
Journal:  Cancer Res       Date:  1992-08-15       Impact factor: 12.701

3.  Autoimmunity and immunotherapy for cancer.

Authors:  Henry Koon; Michael Atkins
Journal:  N Engl J Med       Date:  2006-02-16       Impact factor: 91.245

4.  Gangliosides of human melanoma.

Authors:  T Tsuchida; R E Saxton; D L Morton; R F Irie
Journal:  Cancer       Date:  1989-03-15       Impact factor: 6.860

5.  Myelin-associated glycoprotein shares an antigenic determinant with a glycoprotein of human melanoma cells.

Authors:  A B Noronha; J R Harper; A A Ilyas; R A Reisfeld; R H Quarles
Journal:  J Neurochem       Date:  1986-11       Impact factor: 5.372

Review 6.  Inflammatory demyelinating polyneuropathy: a complication of immunotherapy in malignant melanoma.

Authors:  D A Anthoney; I Bone; T R Evans
Journal:  Ann Oncol       Date:  2000-09       Impact factor: 32.976

7.  Prognostic significance of autoimmunity during treatment of melanoma with interferon.

Authors:  Helen Gogas; John Ioannovich; Urania Dafni; Catherine Stavropoulou-Giokas; Konstantina Frangia; Dimosthenis Tsoutsos; Petros Panagiotou; Aristidis Polyzos; Othonas Papadopoulos; Alexandros Stratigos; Christos Markopoulos; Dimitrios Bafaloukos; Dimitrios Pectasides; George Fountzilas; John M Kirkwood
Journal:  N Engl J Med       Date:  2006-02-16       Impact factor: 91.245

8.  Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma.

Authors:  M D Weiss; C A Luciano; C Semino-Mora; M C Dalakas; R H Quarles
Journal:  Neurology       Date:  1998-12       Impact factor: 9.910

9.  Chronic inflammatory demyelinating polyneuropathy associated with malignant melanoma.

Authors:  S J Bird; M J Brown; M E Shy; S S Scherer
Journal:  Neurology       Date:  1996-03       Impact factor: 9.910

Review 10.  Paraneoplastic neurological syndromes.

Authors:  Jérôme Honnorat; Jean-Christophe Antoine
Journal:  Orphanet J Rare Dis       Date:  2007-05-04       Impact factor: 4.123

View more
  2 in total

1.  Acute Sensory and Autonomic Neuronopathy: A Devastating Disorder Affecting Sensory and Autonomic Ganglia.

Authors:  Joel Gutierrez; Jose-Alberto Palma; Horacio Kaufmann
Journal:  Semin Neurol       Date:  2020-09-09       Impact factor: 3.420

2.  Limbic encephalitis following immunotherapy against metastatic malignant melanoma.

Authors:  Sharfaraz Salam; Timothy Lavin; Ayse Turan
Journal:  BMJ Case Rep       Date:  2016-03-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.